Perform liver function tests before starting, 12 weeks after, during dose evaluation, and regularly thereafter. Patients with diffuse myalgia, muscle pain or weakness, and/or significant increases in CPK are advised to promptly report muscle pain, tenderness, or weakness, especially if accompanied by malaise or fever. Atorvastatin therapy should be discontinued if there is a significant increase in CPK levels or if myopathy is suspected or diagnosed, or in the presence of risk factors for developing secondary renal failure due to rhabdomyolysis.
Daftar Gratis untuk melanjutkan membaca
Sumber terlengkap se-Asia untuk informasi medis, referensi klinis, dan pendidikan
Sign Out
